Discover how FTRE's $7.7B backlog, CRO market growth, and focus on high-margin areas ensure long-term growth, efficiency, and ...

Fortrea (NASDAQ:FTRE – Get Free Report) had its target price decreased by analysts at The Goldman Sachs Group from $22.00 to ...

Fortrea (NASDAQ:FTRE – Get Free Report) had its price objective lowered by investment analysts at Barclays from $25.00 to $12 ...

Detailed price information for Charles River Laboratories Intl (CRL-N) from The Globe and Mail including charting and trades.

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Fortrea Holdings Inc. (FTRE – Research ...

Evercore ISI analyst Elizabeth Anderson CFA maintained a Hold rating on Fortrea Holdings Inc. (FTRE – Research Report) yesterday and set a ...

The company's backlog, which consists of anticipated future revenue from business awards, stood at $7.7 billion as of ...

Q4 2024 Earnings Call Transcript March 3, 2025 Fortrea Holdings Inc. misses on earnings expectations. Reported EPS is $0.18 ...

We reduced our fair value estimate to $15.50 per share from $27.20 to account for greater headwinds as a newly stand-alone company since its spinoff from Labcorp in 2023, which will weigh on revenue ...

Fortrea Holdings Inc. ( ($FTRE) ) has released its Q4 earnings. Here is a breakdown of the information Fortrea Holdings Inc. presented to its ...

Shares of clinical research company Fortrea Holdings (NASDAQ:FTRE) fell 18.5% in the pre-market session after the company ...

Fortrea Holdings Inc. (FTRE) delivered earnings and revenue surprises of -50% and 0.63%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?